2023 World Conference on Lung Cancer (Posters)-EP11.03. Profile of Patients with NSCLC Who Benefit from Immunochemotherapy. Real-World Data from the Multicenter Polish Lung Cancer Group Study

EP11.03. Profile of Patients with NSCLC Who Benefit from Immunochemotherapy. Real-World Data from the Multicenter Polish Lung Cancer Group Study - PDF(Abstract)

Back to course

Pdf Summary

This study analyzed real-world data from patients with stage IV non-small cell lung cancer (NSCLC) who were treated with a combination of pembrolizumab and platin-based chemotherapy. The objective was to identify patient subpopulations that may benefit from this treatment. The study included 339 patients with good performance status and no active brain metastases or genetic alterations. The median progression-free survival (mPFS) and median overall survival (mOS) were estimated using the Kaplan-Meier method. The results showed that the objective response rate was 40.6%, with 12% of patients having progressive disease and 12% dying before the first radiologic assessment. After a median follow-up of 10.5 months, the mPFS and mOS for the overall population were 13 months and 16.8 months, respectively. Specific factors associated with a favorable prognosis included ECOG 0 performance status, smaller tumor size, lower neutrophil/lymphocyte ratio, absence of liver or bone metastases, and a Lung Immune Prognostic Index of 0. Age, PD-L1 expression, and histological type were not significant predictors of outcome. The study found that immunochemotherapy was effective in NSCLC patients regardless of age, PD-L1 expression, and histological type. However, considering certain clinical factors before treatment initiation may help identify the optimal patient population. This study contributes to our understanding of the effectiveness and predictive factors for immunochemotherapy in metastatic NSCLC based on real-world data.

Asset Subtitle

Magdalena Knetki-Wróblewska

Meta Tag

Speaker Magdalena Knetki-Wróblewska

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

stage IV non-small cell lung cancer

pembrolizumab

platin-based chemotherapy

patient subpopulations

progression-free survival

overall survival

objective response rate

favorable prognosis

immunochemotherapy

metastatic NSCLC